BioNTech-Pfizer has postponed the delivery of new batches of its coronavirus vaccine to eight European nations including Spain, the Spanish health ministry said on Monday.
The hold-up is due to a “problem in the loading and shipment process” at its plant in Belgium, the health ministry said in a statement, citing the Spanish branch of Pfizer.
The Spanish health ministry did not specify which European nations aside from Spain have been affected.
The delay comes a day after Europe began its COVID-19 immunization program.
Delay ‘linked to’ temperature
Health Minister Salvador Illa told Spanish radio network SER that the delay was due to a problem “linked to the control of the temperature” of the shipments which was “apparently fixed.”
The vaccine, which uses mRNA technology, is extremely sensitive to heat. It is stored at nearly -70 degrees Celsius (-112°F) ahead of shipping, before being sent to distribution centres in specially designed cool boxes filled with dry ice.
On arrival, it must be kept at 2°C to 8°C for it to remain effective for up to five days.
Several German cities reported similar delays in receiving and administering coronavirus BioNTech-Pfizer on Monday after temperature trackers showed that they may not have been cold enough due to inconsistencies in the cold chain.
Tobias Kurth, epidemiologist and director of the Institute of Public Health at Berlin’s Charite hospital in Berlin told DW that Germany was already struggling with the low number of vaccines available. “The issue is that we don’t have enough vaccines available in the first weeks or months. So the mass vaccination will likely start in March or even April,” he said.
German Health Minister Jens Spahn told public broadcaster ZDF on Monday that the country “was doing everything together with BioNTech-Pfizer” to ramp up domestic production of the coronavirus vaccine in the country.
He said he hoped to get a production facility up and running in Marburg, in the central German state of Hesse, by February or March.
The distribution of an initial 200 million doses of the COVID-19 vaccine developed BioNTech-Pfizer is scheduled to be completed for the EU by September, a spokesman for the EU Commission told news agency Reuters on Monday.
He added that talks were underway to agree the delivery of a further 100 million additional doses which are optional under the contract sealed with the two companies.